These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 27817997)

  • 1. [Vitamin K antagonist, direct oral anticoagulants: Where is the truth?].
    Laroche JP; Schved JF
    J Mal Vasc; 2016 Dec; 41(6):383-388. PubMed ID: 27817997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracranial complications after minor head injury (MHI) in patients taking vitamin K antagonists (VKA) or direct oral anticoagulants (DOACs).
    Riccardi A; Spinola B; Minuto P; Ghinatti M; Guiddo G; Malerba M; Lerza R
    Am J Emerg Med; 2017 Sep; 35(9):1317-1319. PubMed ID: 28400068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Insights into the Pros and Cons of the Clinical Use of Vitamin K Antagonists (VKAs) Versus Direct Oral Anticoagulants (DOACs).
    van Gorp RH; Schurgers LJ
    Nutrients; 2015 Nov; 7(11):9538-57. PubMed ID: 26593943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a tool to identify patients' preference for vitamin K antagonist or direct oral anticoagulant therapy.
    Zolfaghari S; Harenberg J; Froelich L; Wehling M; Weiss C
    Semin Thromb Hemost; 2014 Feb; 40(1):121-8. PubMed ID: 24381153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of body weight on efficacy and safety of direct oral anticoagulants in the treatment of patients with acute venous thromboembolism: a meta-analysis of randomized controlled trials.
    Di Minno MN; Lupoli R; Di Minno A; Ambrosino P; Scalera A; Dentali F
    Ann Med; 2015 Feb; 47(1):61-8. PubMed ID: 25665582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolving Treatments for Arterial and Venous Thrombosis: Role of the Direct Oral Anticoagulants.
    Chan NC; Eikelboom JW; Weitz JI
    Circ Res; 2016 Apr; 118(9):1409-24. PubMed ID: 27126650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The criteria of the Italian Federation of Thrombosis Centres on DOACs: a "real world" application in nonvalvular atrial fibrillation patients already on vitamin K antagonist.
    Barcellona D; Luzza M; Battino N; Fenu L; Marongiu F
    Intern Emerg Med; 2015 Mar; 10(2):157-63. PubMed ID: 25487958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of the Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism.
    Riva N; Ageno W
    Hematol Oncol Clin North Am; 2016 Oct; 30(5):1035-51. PubMed ID: 27637306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current evidence of oral anticoagulant reversal: A systematic review.
    Tornkvist M; Smith JG; Labaf A
    Thromb Res; 2018 Feb; 162():22-31. PubMed ID: 29258056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of intraparenchymal hemorrhage after direct oral anticoagulant or vitamin K antagonist therapy: A systematic review and meta-analysis.
    DiRisio AC; Harary M; Muskens IS; Yunusa I; Gormley WB; Aglio LS; Smith TR; Connors JM; Mekary RA; Broekman MLD
    J Clin Neurosci; 2019 Apr; 62():188-194. PubMed ID: 30472344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
    Beyer-Westendorf J; Ageno W
    Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of Direct Oral Anticoagulants in Special Populations.
    Li A; Lopes RD; Garcia DA
    Hematol Oncol Clin North Am; 2016 Oct; 30(5):1053-71. PubMed ID: 27637307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using direct oral anticoagulants (DOACs) in cancer and other high-risk populations.
    van Es N; Büller HR
    Hematology Am Soc Hematol Educ Program; 2015; 2015():125-31. PubMed ID: 26637711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal Agents for the Direct Oral Anticoagulants.
    Ansell JE
    Hematol Oncol Clin North Am; 2016 Oct; 30(5):1085-98. PubMed ID: 27637309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current challenges and future prospects in oral anticoagulant therapy.
    Czuprynska J; Patel JP; Arya R
    Br J Haematol; 2017 Sep; 178(6):838-851. PubMed ID: 28573648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis.
    Hum J; Shatzel JJ; Jou JH; Deloughery TG
    Eur J Haematol; 2017 Apr; 98(4):393-397. PubMed ID: 28009449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation.
    Senoo K; Lip GY
    Semin Thromb Hemost; 2015 Mar; 41(2):146-53. PubMed ID: 25682085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracranial calcifications under vitamin K antagonists or direct oral anticoagulants: Results from the French VIKING study in older adults.
    Annweiler G; Labriffe M; Ménager P; Ferland G; Brangier A; Annweiler C;
    Maturitas; 2020 Feb; 132():35-39. PubMed ID: 31883661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of New Oral Anticoagulants for Patients with Chronic Kidney Disease.
    Zbigniew K; Hubert S; Andrzej J; Michal S
    Curr Pharm Des; 2018; 24(38):4505-4510. PubMed ID: 30706805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Novel oral anticoagulants and atrial fibrillation in the elderly].
    Hanon O
    Geriatr Psychol Neuropsychiatr Vieil; 2013 Dec; 11(1 Suppl):34-40. PubMed ID: 24463062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.